Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.47%
#2 Status Status +17.94%
#3 GoPlus Security GoPlus Security +14.03%
#4 Ontology Gas Ontology Gas +11.14%
#5 Fake World Assets Fake World Assets +9.28%
#6 DMT-NAT DMT-NAT +9.09%
#7 o1.exchange o1.exchange +7.20%
#8 Provenance Blockchain Provenance Blockchain +7.18%
#9 Nillion Nillion +7.03%
#10 Pons Pons +6.71%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Pozycja w akcjach #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Cena akcji
$0.1502
Ostatnia synchronizacja: 2024-11-04
Kapitalizacja rynkowa
$6.43M
Zmiana (1 dzień)
-5.45%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Renalytix Plc (RNLX)

Kategoria

Healthcare
Marża operacyjna dla Renalytix Plc (RNLX)
Marża operacyjna na dzień August 2026 TTM: -1,293.49%
Według najnowszych raportów finansowych i ceny akcji Renalytix Plc, bieżąca marża operacyjna (TTM) wynosi -1,293.49%. Na koniec 2023 wynosiła -1,244.64%.
Historia marży operacyjnej dla Renalytix Plc od 2018 do 2026
Marża operacyjna na koniec każdego roku
Rok Marża operacyjna Zmień
2026 (TTM) -1,293.49% 0.00%
2024 -1,293.49% 3.92%
2023 -1,244.64% -35.57%
2022 -1,931.72% -11.68%
2021 -2,187.19% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
Marża operacyjna dla podobnych firm lub konkurentów
Firma Marża operacyjna Różnica w marży operacyjnej Kraj
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
12.70% -100.01%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
74.17% -100.06%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
3.33% -100.00%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
-19.76% -99.98%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
0.00% -
US
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.